Point72 Asset Management
NBIX icon

Point72 Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Point72 Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-179,200
Closed -$17.5M – 1625
2022
Q2 		$17.5M Buy
+179,200
New +$16.5M 0.07% 343
2018
Q3 		– Sell
-100,000
Closed -$9.82M – 1147
2018
Q2 		$9.82M Buy
+100,000
New +$8.95M 0.04% 444

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Point72 Asset Management's NBIX Position: Q2 2024 in Review

Point72 Asset Management sold out of Neurocrine Biosciences (NBIX) in Q2 2024, closing a stake of 837,426 shares — an estimated $115M sold.

Point72 Asset Management first reported a position in NBIX in Q1 2015 and held it in 22 quarters. The position peaked at $290M in Q3 2023. 594 funds tracked by Wall St. Rank hold NBIX as of Q2 2024.

  • Point72 Asset Management reported no remaining Neurocrine Biosciences position as of Q2 2024 after selling out during the quarter.
  • Point72 Asset Management sold 837,426 Neurocrine Biosciences shares in Q2 2024, an estimated $115M.
  • Point72 Asset Management first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 22 quarters.
  • Point72 Asset Management's Neurocrine Biosciences position peaked at $290M in Q3 2023.
  • 594 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2024.

Based on Point72 Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.